Drug research

Durvalumab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Imfinzi

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCNCT05733598	Replimune, Inc.	Phase 2	Recruiting	2027-12-01Estimated
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCNCT07459634	Jazz Pharmaceuticals	Phase 2	Recruiting	2028-01-31Estimated
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsNCT05712356	LSTA	Phase 2	Completed	2026-04-05Actual
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerNCT06282575	Jazz Pharmaceuticals	Phase 3	Recruiting	2028-12-01Estimated

Replimune, Inc.RecruitingPrimary completion: 2027-12-01 · Estimated

Trial details

Jazz PharmaceuticalsRecruitingPrimary completion: 2028-01-31 · Estimated

Trial details

LSTACompletedPrimary completion: 2026-04-05 · Actual

Trial details

Jazz PharmaceuticalsRecruitingPrimary completion: 2028-12-01 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.